Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

REVB
Revelation Biosciences Inc
stock NASDAQ

At Close
1/27/2023 3:59:30 PM EST
0.2800USD-1.582%(-0.0045)563,180
0.2600Bid   0.2900Ask   0.0300Spread IEX
Pre-market
1/27/2023 9:13:30 AM EST
0.3040USD+6.854%(+0.0195)0
After-hours
1/27/2023 4:02:30 PM EST
0.2800USD0.000%(0.0000)0
OverviewHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
6.590M
Industry
Biotechnology
REVB Stats
Avg. Vol. 10 Day
1,006,201
Avg. Vol. 30 Day
664,970
Employees
14
Market Cap
6,590,100
Shares Out.
23,536,070
Float
17,500,716
On/Off Exchange
43%/57%
6 Month Beta
1.46
1 Year Beta
1.66
2 Year Beta
1.78
3 Year Beta
1.63
52 Week Low
0.17
52 Week High
2.88
SMA50
0.22
SMA200
0.36
1 Week
+15.13%
1 Month
+47.37%
3 Month
-10.26%
6 Month
-53.30%
1 Year
-88.71%
2 Year
-98.76%
5 Year
-99.03%
Jan 24, 2022
08:06AM EST  Revelation Biosciences Raises $7.76M In Equity Financing   Benzinga
08:00AM EST  Revelation Biosciences Raises $7.76 Million in Equity Financing   GlobeNewswire Inc
Jan 20, 2022
09:07AM EST  Revelation Biosciences Inc. Announces First Group Of Patients Dosed In Phase 2b Viral Challenge Study To Assess Efficacy Of Intranasal REVTx-99 For The Prevention Of H3N2 Influenza Infection   Benzinga
09:00AM EST  Revelation Biosciences Inc. Announces First Group of Patients   GlobeNewswire Inc
Jan 18, 2022
09:07AM EST  Revelation Biosciences Announces First Patient Enrolled, Dosed In Phase 1b Clinical Study Of REVTx-99 For Treatment Of Allergic Rhinitis   Benzinga
More News
Profile
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation's therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.

REVB Stock Summary

Revelation Biosciences Inc (NASDAQ:REVB) stock price today is $0.2800, and today's volume is 563,180. REVB is down -1.582% today. The 30 day average volume is 664,970. REVB market cap is 6.590M with 23,536,070 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC